Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Guest post: Help celebrate #ChampionsofScience: Nominate a pioneering researcher for the 2018 Dr. Paul Janssen Award for Biomedical Research

By Guest Contributor  |    January 29, 2018
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Innovation comes in many forms, including new and expanded uses of existing medicines

By Emma Van Hook  |    January 29, 2018
2017 was a record-breaking year for new drug approvals, with the U.S. Food and Drug Administration (FDA) approving 56 new drugs and biologics. But the innovation did not stop there. As the FDA...   Read More

Fact Check Friday: The truth about the cost of 340B to patients

By Nicole Longo  |    January 26, 2018
The 340B program was designed to increase access to medicines for vulnerable or uninsured patients through safety-net facilities, but all signs point to 340B doing the opposite – distorting the...   Read More

Ask About Adherence: Private-sector collaboration can lead to savings and care improvement

By Carolyn Ha  |    January 25, 2018
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we feature a recent study on medication non-adherence and discuss how a safe...   Read More

PhRMA launches new consumer-facing Let’s Talk About Cost website

By Holly Campbell  |    January 24, 2018
Today, as part of the Let’s Talk About Cost campaign, PhRMA launched LetsTalkAboutCost.org, a national consumer-facing website to provide consumers with easy-to-understand information about the...   Read More

Guess what? Part B drug spending remains stable share of Medicare spending

By Nicole Longo  |    January 23, 2018
Did you know that if you look at medicines in the pipeline for previously unmet medical needs, many are new and exciting immunotherapy treatments that are physician administered? That means these...   Read More

340B Spotlight: New pieces of legislation continue momentum to fix 340B program

By Nicole Longo  |    January 18, 2018
In case you missed it, two new pieces of legislation have been introduced to increase oversight of and fix the 340B program. Before the holidays, Representatives Larry Bucshon and Scott Peters...   Read More

PhRMA urges CMS to share the savings with seniors

By Juliet Johnson  |    January 17, 2018
Yesterday, PhRMA submitted comments in response to the Centers for Medicare & Medicaid Services (CMS) Request for Information (RFI) on sharing a portion of manufacturer rebates directly with...   Read More

ICYMI: Why 2017 medicine approvals matter

By Andrew Powaleny  |    January 12, 2018
This week, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) released its 2017 New Drug Therapy Approvals report. Last year marked an extraordinary...   Read More

Clarity around anti-kickback statute needed to promote innovative payment arrangements

By Michelle Drozd  |    January 10, 2018
You may have recently read about how biopharmaceutical companies and insurers are working together to implement new approaches to paying for medicines, including through results-based contracts...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates